Andrea Riposati, the CEO of Dante Labs

Andrea has held senior positions at leading biotechnology companies, including Genzyme (now Sanofi), Oxford Nanopore Technologies, and Illumina, where he led the development of several sequencing products that have transformed genomic analysis worldwide.

Andrea Riposati is CEO of Dante Labs, which is developing the first portable, affordable, and accurate whole genome sequencing device.

Andrea Riposati is CEO of Dante Labs, which is developing the first portable, affordable, and accurate whole genome sequencing device.

Dante Labs is a spin-out from the University of Cambridge and has been working on this project since 2016. Riposati holds a Ph.D. in Physics from King’s College London and worked as a postdoctoral researcher at Stanford University before joining Dante Labs as Chief Scientific Advisor.

As CEO of Dante Labs, Andrea is leading an extraordinary team at the forefront of innovation in genomic technology.

As CEO of Dante Labs, Andrea is leading an extraordinary team at the forefront of innovation in genomic technology. Dante’s mission is to provide whole genome sequencing to patients worldwide, enabling them to have their data open and easily accessible to doctors and clinicians.

The company’s goal is for all people everywhere – including those without access to healthcare or insurance – to access this technology so they can make informed decisions about their health from the comfort of home.

The company has raised over 80 million dollars from investors such as Andreessen Horowitz, Founders Fund (Peter Thiel), and Steve Jurvetson (DFJ), amongst others.

Andrea is passionate about helping patients and developing technologies that will revolutionize healthcare. He believes that we are on the cusp of a new era in medicine, where we can use technology to improve our understanding of disease and take personalized medicine to a new level.

Andrea has held senior positions at leading biotechnology companies, including Genzyme (now Sanofi), Oxford Nanopore Technologies, and Illumina, where he led the development of several sequencing products that have transformed genomic analysis worldwide. Andrea Riposati is CEO of Dante Labs, which is developing the first portable, affordable, and accurate whole genome sequencing device. Andrea Riposati…